| Person(er):
|
Technical University of Denmark
Email:
Forfatter:
Hersey, Anne
EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridgeshire
Technical University of Denmark
Email:
Technical University of Denmark
Email:
DTU Systems Biology
Email:
Forfatter:
Akhtar, Ruth
EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridgeshire
Forfatter:
Atkinson, Francis
EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridgeshire
Forfatter:
Overington, John P.
EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridgeshire
Technical University of Denmark
Email:
|
| Uddrag:
|
Attrition of drug candidates during pre-clinical development due to toxicity, especially hepatotoxicity and nephrotoxicity, is an important and continuing problem in the pharmaceutical industry. The reasons for this trend may be multifactorial and there is a need to improve toxicity testing paradigms within the industry. Microarray technologies have the ability to generate massive amounts of gene expression information as an initial step to decipher the molecular mechanisms of toxicologic changes, i.e. toxicogenomics. In the context of the eTOX consortium, one of public private partnership within the framework of the European Innovative Medicines Inititative (IMI), we will discuss here how the integration and analysis of toxicogenomics data can help to understanding the mechanism of toxicity
of a compound and so reduce the risk of late-stage failure in pharmaceutical development. |